IRINOTECAN HYDROCHLORIDE TRIHYDRATE

DRUG8 trials

Conditions

CIC-DUX4 bone sarcomasEsophageal CancerEwing sarcomasEwing-like tumors with rare fusionsPancreatic adenocarcinomaResectabel gastric and gastroesophageal junction adenocarcinomaSmall bowel adenocarcinomaUnresectable or Metastatic Colorectal Cancer

Phase 1

Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA

Not yet recruitingCTIS2026-525463-40-00

Les Hopitaux Universitaires De Strasbourgosteosarcomas, chondrosarcomas, Ewing sarcomas +2

Target: 89Updated: 2026-08-20

Phase 2

Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer

CompletedNCT00160875

University Health Network, TorontoEsophageal Cancer

Start: 2009-04-30End: 2011-03-31Updated: 2017-05-04

Preoperative treatment with mFOLFIRINOX (or Gem-Nab-P) +/- isotoxic high-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma: a randomised comparative multicentre phase II study (STEREOPAC)

RecruitingCTIS2022-501181-22-01

Hopital ErasmePancreatic adenocarcinoma

Start: 2023-02-06Target: 256Updated: 2024-01-10

PRODIGE 86-FOLFIRINOX SBA- Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma

RecruitingCTIS2023-505486-92-00

Centre Hospitalier Universitaire De DijonSmall bowel adenocarcinoma

Start: 2024-02-09Target: 170Updated: 2025-11-27

Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma.

Active, not recruitingCTIS2023-509044-96-00

Region SkaneResectabel gastric and gastroesophageal junction adenocarcinoma

Start: 2018-12-21Target: 57Updated: 2024-05-22

A Phase II, Open-Label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants with Colorectal Cancer (CANTOR)

RecruitingCTIS2024-518469-84-00

AstraZeneca ABColorectal cancer

Start: 2025-06-20Target: 69Updated: 2025-06-13

ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Not yet recruitingCTIS2025-523224-45-00

Bristol-Myers Squibb Services Unlimited CompanyUntreated, Unresectable or Metastatic Colorectal Cancer

Target: 33Updated: 2026-03-11

Phase 3

Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of active post-resection/ ablation therapy in patients with metastatic colorectal cancer.

RecruitingCTIS2024-512174-10-00

Charite Universitaetsmedizin Berlin KöRmetastatic colorectal cancer

Start: 2021-11-11Target: 507Updated: 2025-09-04

Related Papers

Abstract A001: Preoperative treatment with mFOLFIRINOX +/- isotoxic high-dose stereotactic body radiation therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): A randomized comparative multicenter phase II trial

Cancer Research2024-01-16

Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.